Astellas

Astellas' Izervay Shows Prolonged Efficacy in 2-Year Study for Geographic Atrophy Treatment

Astellas’ Izervay Shows Prolonged Efficacy in 2-Year Study for Geographic Atrophy Treatment

Anika Sharma

Astellas made a significant acquisition of Iveric Bio earlier this year, primarily motivated by the potential of Iveric’s geographic atrophy ...

Padcev-Keytruda Beats Chemo in Bladder Cancer (ESMO 2023)

Padcev-Keytruda Combo Doubles Survival in First-Line Bladder Cancer Trial (ESMO 2023)

Anika Sharma

ESMO 2023: LBA6 Exciting results from the EV-302 phase 3 trial suggest that the partnership between Seagen and Astellas’ antibody-drug ...

Astellas launches TV campaign for Veozah, a new drug to treat hot flashes and other menopause symptoms

Astellas launches TV campaign for Veozah, a new drug to treat hot flashes and other menopause symptoms

Anika Sharma

Astellas is revving up its efforts to transform the menopause drug Veozah into a standout product, and they’ve just hit ...

Apellis' GA Drug Syfovre Displays Signs of Recovery Amid Challenges

Apellis’ GA Drug Syfovre Displays Signs of Recovery Amid Challenges

Anika Sharma

Apellis Pharmaceuticals, which recently faced workforce reductions due to concerns surrounding its groundbreaking geographic atrophy (GA) drug, Syfovre, is reporting ...

Eric Stonestreet Iveric Bio eye diseases, Geographic atrophy age-related macular degeneration, Iveric Bio Izervay FDA approval, Eric Stonestreet family story eye health, Iveric Bio More to See campaign, Geographic atrophy symptoms and progression, Eric Stonestreet AskAboutGA.com website,

Eric Stonestreet, ‘Modern Family’ Actor, Joins Forces with Astellas’ Iveric Bio to Launch Vision Health Awareness Initiative

Anika Sharma

Iveric Bio, an Astellas-acquired biotech company, has initiated a compelling awareness campaign for a disease it recently gained FDA approval ...

astellas, izervay, geographic atrophy, eye disease, phase 3 trial, primary endpoint, dry AMD

Astellas claims positive results for Izervay in geographic atrophy but remains vague on data

Anika Sharma

Astellas, having recently secured FDA approval for its drug Izervay to treat geographic atrophy (GA), is now in direct competition ...

Poseida Therapeutics Lands $50M Investment from Astellas Pharma

Astellas Buys $50M Stake in Poseida, Boosting Gene Therapy Pipeline

SG Tylor

Source – Poseida Therapeutics Japanese pharmaceutical company Astellas is making a strategic move by investing $50 million to acquire an ...

Astellas Partners with PeptiDream to Develop Protein Degraders

With the PeptiDream agreement, Astellas incorporates protein degraders

SG Tylor

Source – Astellas  Astellas has continued its focus on protein degrader drugs, announcing its second partnership in this category in ...

Astellas Faces Setback in the US Patent Trial for Myrbetriq

Astellas Faces Setback in the US Patent Trial for Myrbetriq

SG Tylor

Source – Astellas An important patent that Astellas has on the urinary incontinence medicine Myrbetriq has been declared invalid by ...